Targeting Inflammation at the Source: Advancing ENGI-004 to Deliver Tissue-Selective Immune Modulation in Atopic Dermatitis
- Exploring a novel tissue-targeted approach to immunomodulation by engaging MHC-related receptors enriched at barrier tissues, including the skin, to concentrate activity where disease occurs
- Leveraging AI-guided protein engineering to optimize efficacy and safety through precise delivery of inhibitory signals to inflamed tissues while minimizing systemic immune suppression
- Translating ENGI-004 from discovery toward clinical development to establish a differentiated therapeutic strategy for atopic dermatitis and other barrier tissue inflammatory diseases